MGF
Also known as: Mechano Growth Factor, IGF-1Ec
MGF (Mechano Growth Factor) is a splice variant of IGF-1 expressed in response to mechanical loading, studied in early research for its reported role in muscle repair. It is not approved for human use in Australia.
- Category
- Growth Factor
- Reported half-life
- Not well established; the unspliced peptide is reported to be short-lived
- Common forms
- Lyophilised powder for reconstitution, Injectable solution
- Research status
- Not approved for human use in Australia; investigated in preclinical and laboratory research only. No marketed human therapeutic product.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to support activation of muscle satellite (stem) cells
- Early research indicates a role in muscle repair after mechanical stress
- Users report interest in recovery and muscle growth
- Claimed to act locally rather than systemically
How it is reported to work
MGF is reported to be an alternatively spliced variant of IGF-1 (IGF-1Ec) produced by muscle in response to mechanical loading or damage. Its distinctive C-terminal peptide is proposed to help activate satellite cells that contribute to muscle repair before the molecule is processed toward IGF-1 signalling. These mechanisms are drawn from early laboratory and animal research and are not established in humans.
Background
MGF (Mechano Growth Factor) is a splice variant of IGF-1 (IGF-1Ec) that muscle tissue is reported to produce in response to mechanical loading or damage. It has attracted research and online interest for its reported role in the early steps of muscle repair. This page is educational information, not medical advice.
What the research actually shows
MGF has been studied mostly in laboratory and animal models, where it is reported to help activate satellite cells involved in muscle repair. Human clinical trials on synthetic MGF as an intervention are essentially absent, so benefits and safety remain unproven.
| Evidence type | Status |
|---|---|
| Laboratory/animal research | Present |
| Human trials | Lacking |
| Australian approval | None |
What people use it for (reported)
Online, people report using MGF in attempts to support muscle recovery and growth. These are anecdotal reports, not validated clinical results. Studies suggest a local satellite-cell mechanism, but reported benefits should not be read as established facts.
Things to be aware of
MGF is not approved for human use in Australia. Growth factor pathways carry theoretical concerns around cell proliferation, and grey-market product identity and purity cannot be verified by sight.
If you have a recovery or health concern, the appropriate step is to talk to a qualified healthcare professional rather than self-experimenting. This article is not an endorsement and does not recommend obtaining or using MGF.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported to support activation of muscle satellite (stem) cells involved in repair
- Reported interest in faster recovery from intense or damaging training
- Reported to act locally at the site of injection rather than systemically
- Reported to complement IGF-1 signalling during early tissue repair
Common side effects
- Reported injection-site reactions such as redness, swelling or soreness
- Reported localised pain or irritation at the injection point
- Reported temporary fatigue or lethargy after dosing
- Reported mild headaches in some users
Rare / serious side effects
- Theoretical concerns around abnormal cell proliferation from growth-factor signalling
- Reported risk of infection or abscess from non-sterile grey-market preparations
- Reported allergic-type reactions to impurities in unverified product
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of MGF. Listed so you can make an informed decision, not to suggest any use is safe.
- Overuse is reported to over-stimulate local growth-factor pathways, with concern that chronic misuse could promote uncontrolled cell proliferation.
- Frequent high-dose use is reported to risk localised tissue overgrowth or scarring around repeated injection sites.
- Stacking with other growth factors is reported to raise IGF-1 signalling excessively, a pattern linked in concern to organ strain and increased health risk.
- Reliance on unverified grey-market vials is reported to carry contamination and dosing-error risks due to unknown purity.
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Users report subtle local effects within days, with any repair-related changes accumulating over several weeks of repeated use.
First effects
Reported localised soreness or pump near injection sites
Noticeable change
Reported subjective recovery and repair improvements
Clear results
Reported cumulative muscle-repair effects with continued use
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take MGF. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection, often localised near the targeted muscle |
|---|---|
| Typical reported dose | Reported community figures of roughly 200–400 mcg per dose |
| Frequency | Reported as dosed around training, e.g. pre, intra or post-workout on training days |
| Cycle length | Reported in short runs, often a few weeks at a time |
Reported reconstitution (mg → units)
Illustration only: a 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL. A 300 mcg (0.3 mg) dose is about 0.12 mL = 12 units on a U-100 insulin syringe.
Work out the units for your vial → CalculatorCommonly reported as short post-training pulses several times weekly over a few-week block, often timed around training, framed as anecdotal reporting and not medical advice. Not approved for human use in Australia.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Safety notes
MGF is not approved by the TGA for human use in Australia, and human safety data is essentially lacking. Growth factor pathways can carry theoretical risks including effects on cell proliferation, and grey-market product purity cannot be verified by consumers. Anyone considering it should first consult a qualified healthcare professional.